Saphnelo (anifrolumab-fnia) for systemic lupus erythematosus
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0202 alerts
Get alerted when Policy CC-0202 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-benefit coverage and prior authorization for Saphnelo in adults with moderate-to-severe active systemic lupus erythematosus (SLE). It establishes initial and continuation criteria, non-approval conditions, approval durations, quantity limits, and applicable billing codes.
The 2026 annual review removed the SLEDAI score requirement and specific anti-dsDNA thresholds from the Saphnelo criteria.
The 2026 annual review removed continuation criteria addressing active central nervous system lupus and lupus nephritis and consolidated these conditions into non-approval criteria.
The policy added quantity limits for the 120 mg/0.8 mL Saphnelo prefilled syringe or autoinjector.
The policy removed the prior restriction against use with cyclophosphamide.
The policy removed the SLEDAI score requirement and specific anti-dsDNA thresholds from the clinical criteria.
The policy removed continuation criteria addressing active central nervous system lupus and lupus nephritis.
The policy removed selected non-approvable criteria.
The policy added the Saphnelo prefilled syringe and autoinjector dosage forms to the quantity limits.
The policy previously removed the restriction against using Saphnelo with cyclophosphamide.
The policy history records clarification of diagnosis requirements for systemic lupus erythematosus.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.